Development of RADARS-based Therapy to Treat Fusion Molecule Driven Pediatric Malignancies |
Boston Children’s Hospital / Alan B. Cantor, MD, PhD |
Innovation Grants |
2023 |
Massachusetts |
Preclinical Studies of Gli1 Inhibition in Ewing Family Tumors
|
Children’s Hospital Los Angeles / William May |
Innovation Grants |
2008 |
California |
Developing Immune-modulatory Strategies Against Primary and Metastatic Tumors in the Central Nervous System |
Case Western Reserve University / Alex Huang, MD, PhD |
Innovation Grants |
2012 |
Ohio |
Identifying Epigenetic Mechanisms Impacting Neuroblastoma Genome Stability and Drug Response |
Massachusetts General Hospital / Johnathan Whetstine, PhD |
Innovation Grants |
2015 |
Massachusetts |
Development of MicroRNA-Nanoparticles to Treat Childhood Acute Leukemia Carrying MLL Rearrangements |
University of Cincinnati College of Medicine / Jianjun Chen, PhD |
Innovation Grants |
2013 |
Ohio |
Enhancing Pediatric Sarcoma Immunotherapy by Drug Induced Expression of Tumor-Specific Cryptic Neoantigens |
University of Minnesota / David Largaespada, PhD |
Innovation Grants |
2016 |
Minnesota |
Identifying New Therapeutic Targets in Fibrolamellar Hepatocellular Carcinoma |
Stanford University / Julien Sage, PhD |
Innovation Grants |
2018 |
California |
CDK12 Links Radiation Response to PARPi Sensitivity in Pediatric Glioma |
University of Colorado Denver_ Anschutz Medical Campus / Nathan Dahl, MD |
Innovation Grants |
2023 |
Colorado |
Inhibition of Cathepsins to Treat Neuroblastoma |
Alfred I duPont Hospital for Children / Robert Mason |
Innovation Grants |
2008 |
Delaware |
Development of the Next Generation FLT3 Inhibitors for Pediatric AML and Infant ALL |
The Johns Hopkins University School of Medicine / Donald Small, MD, PhD |
Innovation Grants |
2012 |
Maryland |